

Increased Risk of Ischemic Events Upon Discontinuation of Prasugrel After 12 or 30 Months of Therapy Following Placement of the TAXUS Liberté Paclitaxel- Eluting Coronary Stent

Kirk N. Garratt, Ronald D. Jenkins, Thomas K. Pow, W.
Douglas Weaver, Laura M. Mauri, Dean J. Kereiakes,
Kenneth J. Winters, Thomas Christen, Dominic J.
Allocco, and David P. Lee



TAXUS
Liberté

Background



- TAXUS Liberté Post-Approval Study (TL-PAS) was designed to provide long-term safety and efficacy data on the TAXUS Liberté paclitaxel-eluting coronary stent with concomitant prasugrel and ASA in a broad spectrum of patients
- TL-PAS contributed to the Dual Antiplatelet Therapy (DAPT) Study by randomizing TAXUS Liberté stent patients to blinded thienopyridine treatment, using prasugrel or matched placebo, from 12 through 30 months after the index procedure
- The TL-PAS data are being presented separately following guidance from the TL-PAS Data Monitoring Committee (DMC)

TL-PAS and DAPT



- TL-PAS represented 1 of 4 manufacturer sponsored studies that contributed subjects to the DAPT Study
 - TL-PAS patients represent the largest portion of PES patients & the largest cohort receiving prasugrel in the DAPT Study
- Each contributing study was required to employ the same randomization criteria, end point definitions, and follow-up specified by the DAPT Study
- The overall DAPT Study, but not the individual contributing studies, was designed with sufficient power to compare the endpoints
 - TL-PAS (and the other studies contributing to DAPT) had separate safety DMC & CEC

DAPT Study Endpoints



Two co-primary effectiveness endpoints

- MACCE (all-cause death, MI or stroke) occurring between 12-30 months post-procedure
- Definite/probable stent thrombosis (ST) occurring between 12-30 months post-procedure

Primary safety endpoint

- Major bleeding, defined as “moderate” or “severe” by GUSTO classification occurring between 12-30 months post-procedure


For MI and ST (probable or definite), Academic Research Consortium (ARC) definitions were used: Cutlip et al *Circulation* 2007
For “moderate” or “severe” bleeding, Global Utilization of Streptokinase and TPA for Occluded Arteries (GUSTO) definitions were used: GUSTO investigators *N Engl J Med* 1993

Study Oversight




- Potential endpoint events were adjudicated by the TL-PAS Clinical Events Committee (CEC) using uniform definitions; the CEC was blinded to treatment assignment
- Overall DAPT Study data were monitored by the DAPT Study DMC
- Safety within TL-PAS was monitored by the TL-PAS DMC

Enrollment Scheme




Randomization at 12 months permitted only for consenting patients free of death, CABG, stroke, stent thrombosis or major bleeding event at any time after stent placement, and free of MI and any PCI beyond 6 weeks after initial stent placement, and who has been compliant with antiplatelet therapy.

TL-PAS Patient Flow



**Randomization at 12 months permitted only for consenting patients free of death, CABG, stroke, stent thrombosis or major bleeding event at any time after stent placement, and free of MI and any PCI beyond 6 weeks after initial stent placement, and who has been compliant with antiplatelet therapy.*

TL-PAS Patient Flow



*Randomization at 12 months permitted only for consenting patients free of death, CABG, stroke, stent thrombosis or major bleeding event at any time after stent placement, and free of MI and any PCI beyond 6 weeks after initial stent placement, and who has been compliant with antiplatelet therapy.

Baseline Characteristics

Characteristic (%, unless noted)	12-month Prasugrel + ASA N=1093 patients	30-month Prasugrel + ASA N=1098 patients	Characteristic (%, unless noted)	12-month Prasugrel + ASA N=1093 patients	30-month Prasugrel + ASA N=1098 patients
Male	74.6	76.3	PCI History	30.9	28.1
Age (years)	59.2 ± 9.5	59.6 ± 9.7	CABG History	12.8	12.0
Age >75 years	2.7	3.8	Bleeding disorder	0.3	0.5
Weight <60 kg	3.5	3.2	Stable angina	30.6	29.4
Diabetes*	27.3	31.4	Unstable angina	32.6	34.5
Metabolic Syndrome	12.5	15.7	Silent ischemia	8.0	8.3
Hyperlipidemia*	69.7	68.1	MI	28.2	27.3
Hypertension*	71.0	71.9	NSTEMI	17.9	15.5
MI History	20.3	20.3	STEMI	9.5	10.7

Numbers are % or mean ± SD; *Medically-treated; MI=myocardial infarction; PCI=percutaneous coronary intervention; CABG=coronary artery bypass graft

Baseline Characteristics



Characteristic	12-month Prasugrel + ASA	30-month Prasugrel + ASA	Characteristic	12-month Prasugrel + ASA	30-month Prasugrel + ASA
Emergent procedure [‡]	22.7	22.6	Lesions treated* (mean ± SD)	1.3 ± 0.7	1.4 ± 0.7
RVD [†] (mm)	3.0 ± 0.5	3.0 ± 0.50	Vessels treated* (mean ± SD)	1.2 ± 0.4	1.1 ± 0.4
Length [†] (mm)	15.8 ± 9.9	15.3 ± 8.7	Stents Implanted* (mean ± SD)	1.4 ± 0.8	1.5 ± 0.8
DS [†] (%)	85.6 ± 12.0	85.5 ± 11.6	Stent length per patient* (mean ± SD)	28.3±19.0	28.4±18.3
<i>De novo</i> lesions [†] (%)	96.2	96.4	B2 lesion [†] (%)	20.1	21.6
Pre-dilatation performed [‡] (%)	54.1	53.7	C lesion [†] (%)	19.4	18.5


RVD=reference vessel diameter; DS=diameter stenosis; SD=standard deviation

12-month Prasugrel + ASA: N=1093 Patients*, N=1465 Lesions[†], N=1142 Procedures[‡]

30-month Prasugrel + ASA: N=1098 Patients*, N=1492 Lesions[†], N=1138 Procedures[‡]

Co-Primary Endpoint: MACCE at 540 days

Death, ARC MI, Stroke







Cumulative KM Event Rate ± 1.5 SE; log-rank P value; HR=Hazard Ratio [95% confidence interval]

Results: MACCE – Death, Stroke, and MI


— 12-mo Prasugrel + ASA

— 30-mo Prasugrel + ASA




Cumulative KM Event Rate ± 1.5 SE; log-rank P value; HR=Hazard Ratio [95% confidence interval]

Results: ARC MI




Cumulative KM Event Rate ± 1.5 SE; log-rank P value; HR=Hazard Ratio [95% confidence interval]

Co-Primary Endpoint: Definite/Probable ARC Stent Thrombosis at 540 days




Results: ARC MI related to ST



Cumulative KM Event Rate ± 1.5 SE; log-rank P value

Results: ARC MI not related to ST



Cumulative KM Event Rate ± 1.5 SE; log-rank P value


Interim DMC Review



- In mid-2013, TL-PAS DMC noted the early increase in spontaneous ischemic events following withdrawal of active prasugrel therapy in patients randomized to 12 month and 30 month DAPT
 - TL-PAS DMC recommended that randomized treatment be unblinded for TL-PAS patients who had not yet completed 30 month follow-up to allow discussion of continuing open-label prasugrel
- Unblinding affected a very small number of patients (N=27) and was conducted at the 30 month time point to minimize impact of DAPT Study

Results: Major Bleeding

GUSTO Moderate/Severe



Limitations



- **Analysis of TAXUS Liberté patients from TL-PAS was not powered for DAPT Study endpoints**
- **TL-PAS exclusion criteria included a history of prior cerebrovascular or bleeding events; subjects with very low body mass or advanced age may have been under-represented**
- **Randomized subjects tolerated 12 months prasugrel plus aspirin without major bleeding before randomization**

- **In patients receiving the TAXUS Liberté paclitaxel-eluting stent, 30-month prasugrel + ASA was associated with:**
 - Significant reduction in MACCE (HR = 0.407) primarily related to a reduction in ARC MI (HR = 0.255)
 - ARC MI related to ST (@ 540 d: 0.0% vs 2.6%) KR12
 - ARC MI non related to ST (@ 540 d: 1.9% vs 4.5%)
 - Significant reduction in ARC definite/probable ST (HR = 0.063)
- **30-month prasugrel + ASA was not accompanied by a significant increase in GUSTO moderate or severe bleeding (HR 1.438)**

Slide 20

KR12

Used % rather than HR because the HR 0.000
[0.000, NA]

Roy, K, 10/23/2014

- **Withdrawal of prasugrel resulted in apparent loss of protection, with an early increase in ischemic events, when stopped after 12 months or 30 months**
 - Principal risk was increased MI
 - Difference significant within 90 days of prasugrel cessation
- **Whether the reduction in late ischemic events demonstrated with prasugrel + ASA and the TAXUS Liberté paclitaxel-eluting coronary stent would be observed with other dual anti-platelet regimens and/or other drug-eluting stents will require further insights from the larger DAPT Study**